Monoclonal Antibodies for COVID-19

New Avenues to Pre-Exposure Prophylaxis

As the COVID-19 pandemic continues to devastate the world, it is important for clinicians to recognize the most vulnerable populations, such as immunocompromised people. They are unlikely to mount a full response to COVID-19 vaccinations and have a higher risk of both severe outcomes if infected and easier transmission to uninfected people. An Emergency Use Authorization (EUA) was recently granted for preexposure prophylaxis in immunocompromised people, and it is critical that clinicians are aware of data, EUA criteria, and patient prioritization strategies.

These activities are jointly provided by Global Education Group and Integritas Communications.

 

These activities are supported by an educational grant from AstraZeneca.

Image Webcast Series

credit amount 0.25

credit type CME/AANP

expiration 03/25/2023

Image POC101
Immunocompromised Patients and COVID-19 Risks

Activity 2

Jonathan Li, MD, MMSc & Lewis Teperman, MD, FACS
MODULE 2
Begin Activity

credit amount 0.25

credit type CME/AANP

expiration 04/01/2023

Image POC101
Point-of-Care Use of Anti-SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis

Activity 3

Jonathan Li, MD, MMSc & Lewis Teperman, MD, FACS
MODULE 3
Begin Activity

credit amount 0.25

credit type CME/AANP

expiration 04/07/2023

Resource

Monoclonal Antibodies for COVID-19

New Avenues to Pre-Exposure Prophylaxis